References
1. Benet, L. Z. 1985. Pharmacokinetics and metabolism of bepridil. Am J Cardiol 55(7):8c-13c.
2. Aonuma. K., Shiga, T., and H. Atarashi, et al. 2017. Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - digest version. Circ J 81(4):581-612.
3. Yasuda, M., Nakazato, Y., and A. Sasaki, et al. 2006. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 70(6):662-666.
4. Yamashita, T., Ogawa, S., and T. Sato, et al. 2009. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study). Circ J 73(6):1020-1027.
5. Shiga, T., Suzuki, A., Naganuma, M., Hosaka, F., Shoda, M., and N. Hagiwara. 2011. Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil. Circ J 75(6):1334-1342.
6. Harder, D. R., and N. Sperelakis. 1981. Bepridil blockade of Ca2+-dependent action potentials in vascular smooth muscle of dog coronary artery. J Cardiovasc Pharmacol 3(4):906-914.
7. Anno, T., Furuta, T., Itoh, M., Kodama, I., Toyama, J., and K. Yamada. 1984. Electromechanical effects of bepridil on rabbit isolated hearts. Br J Pharmacol 81(1):41-47.
8. Wang, J. C., Kiyosue, T., Kiriyama, K., and M. Arita. 1999. Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes. Br J Pharmacol 128(8):1733-1738.
9. Epstein, A. E., DiMarco, J. P., and K. A. Ellenbogen, et al. 2013. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127(3):e283-e352.
10. Eldar, M., Griffin, J. C., and J. A. Abbott, et al. 1987. Permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol 10(3):600-607.
11. Eldar, M., Griffin, J. C., and G. F. Van Hare, et al. 1992. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 20(4):830-837.
12. Oosterhoff, P., Thomsen, M. B., and J. N. Maas, et al. 2010. High-rate pacing reduces variability of repolarization and prevents repolarization-dependent arrhythmias in dogs with chronic AV block. J Cardiovasc Electrophysiol 21(12):1384-1391.
13. Keren, A., Tzivoni, D., Golhman, J. M., Corcos, P., Benhorin, J., and S. Stern. 1981. Ventricular pacing in atypical ventricular tachycardia. J Electrocardiol 14(2):201-205.
14. Tötterman, K. J., Turto, H., and T. Pellinen. 1982. Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). Acta Med Scand Suppl 668:28-33.
15. Davison, E. T.. 1985. Amitriptyline-induced torsade de dointes. Successful therapy with atrial pacing. J Electrocardiol 18(3):299-301.
Figure Legends
Figure 1. 12-lead electrocardiogram at pacemaker clinic
Figure 2. Electrocardiogram and arterial blood pressure monitoring at the electrophysiology laboratory. A. QT prolongation just after pacemaker reprograming to lower heart rate setting. B. TdP occurrence and termination by 150 J defibrillation (black arrow). ABP: arterial blood pressure; TdP: torsade de pointes.